Follow us on Twitter
twitter icon@FreshPatents

G Proteins patents

Bulk PDF Downloads
      

This page is updated frequently with new G Proteins-related patent applications.




 Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof patent thumbnailnew patent Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof
An antibody or antigen-binding fragment thereof which specifically binds the α3 domain of a hla-g protein, in particular binds the β2-microglobulin free hla-g protein exhibiting an α3 domain. The nucleic acid molecules encoding a human hla-g α3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to hla-g proteins, and/or improving or treating conditions showing hla-g+ lesions, and/or improving or treating a neoplasic condition or disease.
Invectys


 Il-13 binding proteins and uses thereof patent thumbnailnew patent Il-13 binding proteins and uses thereof
Novel anti-il-13 antigen-binding proteins such as antibodies and antigen-binding fragments thereof are provided. Methods of using the proteins to reduce il-13 activity and to treat il-13-associated diseases and conditions are further provided..
Medimmune Limited


 Tnf-alpha binding proteins patent thumbnailnew patent Tnf-alpha binding proteins
Tnf-α binding proteins, including chimeric, cdr-grafted, and humanized antibodies that bind tnf-α are provided. Binding proteins have high affinity for tnf-α and neutralize tnf-α activity.
Abbvie Inc.


 Pharmaceutical compositions patent thumbnailnew patent Pharmaceutical compositions
A composition including lactoferrin and immunoglobulin, wherein the composition does not substantially include one or more of the following proteins: lactoperoxidase, lactoglobulin, albumin.. .
Probiotec Limited


 Methods for producing a paired tag from a nucleic acid sequence and methods of use thereof patent thumbnailMethods for producing a paired tag from a nucleic acid sequence and methods of use thereof
Methods for producing a paired tag from a nucleic acid sequence are provided in which the paired tag comprises the 5′ end tag and 3′ end tag of the nucleic acid sequence. In one embodiment, the nucleic acid sequence comprises two restriction endonuclease recognition sites specific for a restriction endonuclease that cleaves the nucleic acid sequence distally to the restriction endonuclease recognition sites.
Applied Biosystems Llc


 Tslp binding proteins patent thumbnailTslp binding proteins
The present disclosure relates to tslp binding proteins, such as anti-tslp single variable domains, polynucleotides encoding such tslp binding proteins, pharmaceutical compositions and kits comprising said tslp binding proteins and methods of manufacture. The present invention also concerns the use of such tslp binding proteins in the treatment of diseases associated tslp signaling, such as asthma..
Glaxosmithkline Intellectual Property Development Limited


 Anti-ngf antibodies and their use patent thumbnailAnti-ngf antibodies and their use
The present disclosure encompasses ngf binding proteins, specifically to antibodies that are chimeric, cdr grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting ngf and for inhibiting ngf activity, e.g., in a mammal subject suffering from a disorder in which ngf activity is detrimental..
Zoetis Belgium S.a.


 Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming patent thumbnailMethods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject..
Wayne State University


 Modified binding proteins inhibiting the vegf-a receptor interaction patent thumbnailModified binding proteins inhibiting the vegf-a receptor interaction
The present invention relates to binding proteins specific for vegf-a, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits vegf-axxx binding to vegfr-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety.
Molecular Partners Ag


 Active ingredient capsules patent thumbnailActive ingredient capsules
Active ingredient capsules are proposed which are obtainable by, with the input of mechanical and thermal energy, (a) dissolving and/or dispersing proteins, polysaccharides and cellulose derivatives in water, (b) adding the active ingredients to be encapsulated, (c) hardening the resulting coacervates with the addition of tannins and optionally (d) then subjecting them to a spray drying.. .
Symrise Ag


Desmoglein 2 (dsg2) binding proteins and uses therefor


The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.. .
University Of Washington Through It's Center For Commercialization


Agent for preventing or treating spinocerebellar ataxia


To provide a compound which enables treatment or prevention of spinocerebellar ataxia, analyses were carried out based on a screening using a spinocerebellar ataxia type 1 (sca1) fly model and on the like. As a result, the following proteins ameliorating the pathology of spinocerebellar ataxia were identified: rpa1, pnkp, xrcc3, xrcc4, ccnh, pole, polh, and peri.
National University Corporation Tokyo Medical And Dental University


Methods and products for expressing proteins in cells


The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.


Methods and products for expressing proteins in cells


The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.


Il-17 receptor a antigen binding proteins


The present invention relates to il-17 receptor a (il-17ra or il-17r) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by il-17 receptor a activation by one or more il-17 ligands. The present invention relates to the identification of neutralizing determinants on il-17 receptor a (il-17ra or il-17r) and antibodies that bind thereto.
Kirin-amgen, Inc.


Designed ankyrin repeat proteins binding to hepatocyte growth factor


New designed ankyrin repeat proteins with binding specificity for hgf are described, as well as nucleic acids encoding such hgf binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.. .
Molecular Partners Ag


Designed repeat proteins binding to serum albumin


New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin..
Molecular Partners Ag


Galectin-3 as immunological target


Annexina2 (anxa2), a member of the annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. Annexina2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane annexina2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas.
The Johns Hopkins University


Methods for making proteins containing free cysteine residues


The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness.
Bolder Biotechnology, Inc.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Article and controlling oral-originated obligate and facultative anaerobes and aerobic bacteria pathogens related to systemic disease


Method of treating oral subgingival biofilms having obligate anaerobes, facultative anaerobes, aerobic bacteria and other micro-organisms (collectively oral pathogens) associated with certain systemic diseases present within a subgingival biofilm having proteins and amino acids, the steps including providing a periodontal medicament delivery tray having a seal against a patient's adjacent gums containing the oral biofilms with the systemic disease, said seal formed so as to have no contact with teeth, applying to the gingival tissue (sulcus or periodontal pocket) a biofilm penetrating antimicrobial agent, removing the imbedded oral pathogens from the gingival tissue following at least one applying of the antimicrobial agent to the gingival tissue; repeatedly administering colloidal hydrogen peroxide gel to the gingival tissue following the removing; and following each administering cleaning the gingival tissue with a cleaning agent directly following the administering of the colloidal hydrogen peroxide gel for modifying the environment from anaerobic to commensal.. .

Solid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip


Pipette tips comprising aldehyde-reactive or amino-reactive chemical moieties or other chemical moieties capable of conjugating to one or more reactive groups of amino acid side chains or protein modifications and methods for preparing the tips are provided. In addition, a high throughput method for identifying proteins, glycoproteins, and glycans in a plurality of samples using the pipette tips is also provided..
The Johns Hopkins University


Method for detecting proteins by means of aptamers


The present invention describes a method for an in vitro detection of a first protein in a sample, comprising the steps of: a) separating the sample by means of a native separation method; b) transferring the separated sample onto a membrane; c) contacting the membrane with an aptamer which specifically binds to the first protein; and d) detecting the first protein by detecting the aptamer bound to the first protein.. .
Technische Universität Berlin


Method for selecting a single cell expressing a heterogeneous combination of antibodies


Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing..
Merus B.v.


Microbial analysis


The present invention is concerned with a method of identifying microbial strains (e.g. From a cell culture), the method comprising; i) a lipid extraction step, comprising extraction of phospholipids from the microbe, suitably with an extraction composition comprising more than 50 vol % meoh; ii) a sample preparation step, comprising preparation of a maldi sample incorporating the extracted lipids; iii) a data gathering step, comprising performing maldi-based mass spectrometry on the maldi sample, and iv) a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbial strain.
Kratos Analytical Limited


Methods for the selection of binding proteins


This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mrna display and yeast surface display in a way that takes advantage of the desirable attributes of both processes..
Bristol-myers Squibb Company


Synthetic single domain antibody


The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d ab) and its use in generating synthetic single domain antibody library (hs2d ab-l1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics..
Centre National De La Recherche Scientifique - Cnrs


Chimeric factor h binding proteins (fhbp) and methods of use


Chimeric fhbps that can elicit antibodies that are bactericidal for different fhbp variant strains of n. Meningitidis, and methods of use, are provided..
Children's Hospital & Research Center Oakland


Activated formylglycine-generating enzymes and methods of producing and using the same


The present disclosure provides activated formylglycine-generating enzymes (fge), methods of producing activated fge, and their use in methods of producing a protein comprising a formylglycine (fgly) residue. The methods of producing activated fge, as well as methods of use of activated fge in producing fgly-containing proteins, include both cell-based and cell-free methods.
R.p. Scherer Technologies, Llc


Tm4sf1 binding proteins and methods of using same


This present invention relates to compounds (e.g., tm4sf1 binding proteins, e.g., anti-tm4sf1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of seq id no: 1. In particular, the compounds of the invention are capable of being internalized into a tm4sf1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of seq id no: 1.
Beth Israel Deaconess Medical Center, Inc.


Mice that produce antigen-binding proteins with ph-dependent binding characteristics


Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
Regeneron Pharmaceuticals, Inc.


Methods and kits for isolation and analysis of a chromatin region


The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas


Modified zinc finger binding proteins


Disclosed herein are compositions and method comprising non-canonical (e.g., non-c2h2) zinc finger proteins.. .
Sangamo Biosciences, Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases


On the basis thereof, the authors of the present invention have combined a peptide, a protein or a polypeptide associated with a “conformational disease” with a biologically active or functional hsp, resulting in a different immunoactive complex which is advantageous for treating the “conformational disease” in question associated with the peptide, protein or polypeptide used.. .

Pharmaceutical or nutraceutical composition


The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions.

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Common light chain mouse


A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.


Icos binding proteins


The present invention relates to an icos binding protein, or antigen binding portion thereof that is an agonist human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited


Biomarkers for mycobacterium avium paratuberculosis (map)


Described are methods and products useful for identifying subjects with mycobacterium avium subspecies paratuberculosis (map). A number of protein antigens secreted into culture filtrate by map are identified and binding proteins selective for these antigens are demonstrated to be useful for detecting subjects with map infections including subjects with johne's disease..
University Of Guelph


Memory performance and prevention and treatment of neurodegenerative diseases


The present technology relates to improvement of memory performance and the prevention or treatment of brain disorders associated with memory loss. In particular, the invention relates to the use of centaurin-α1 (centa1), centa1 activating proteins, and centa1 effector proteins as therapeutic targets to improve memory and cognitive performance in a normal subject and/or in a subject with neurological disorders associated with memory and/or cognitive impairments, such as alzheimer's disease..
Max Planck Florida Institute For Neuroscience


Blood clot-dissolving proteins produced in seeds


Transgenic plants in which blood-clot dissolving proteins are produced in seeds of the plants are provided. Expression of the proteins is driven by a seed specific or selective promoter.
Northeastern State University


Electron spin labeled ice binding compounds used for carrying paramagnetic centers for dynamic nuclear polarization


Spin labeled ice binding compounds (ibcs) including ice binding proteins (ibps), also called antifreeze proteins (afps) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (dnp), for enhancing nuclear magnetic resonance (nmr) signal intensities. Use of spin labeled ibcs to perform dnp exploits the ibcs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high dnp efficiency.
The Trustees Of California State University


Method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation


The invention relates to a method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation. Said method comprises: a) sampling, in at least one area of the body of the person, the follicles or bulbs of head and/or body hair of the person; b) extracting proteins from cells of said sampled hair bulbs or follicles, wherein said proteins, including proteins from the atm system, are subjected to phosphorylation and/or acetylation induced by ionizing radiation; and c) analyzing at least two types of extracted proteins and interpreting the analysis results in order to determine the irradiation dose in the or each sampling area..
Acubens


Composition and methods for culturing cells


The present disclosure provides compositions for in vitro culture of cells. The present disclosure provides methods for in vitro culture of cells.
The Regents Of The University Of California


Clickable polymers and gels for microarray and other applications


Fabrication of arrays, including glycan arrays, that combines the higher sensitivity of a layered si—sio2 substrate with novel immobilization chemistry via a “click” reaction. The novel immobilization approach allows the oriented attachment of glycans on a “clickable” polymeric coating.

Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof


This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a cd154 (cd40l) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized fab fragment comprising a variable heavy chain sequence according to seq id no: 1 and comprising a variable light chain sequence according to seq id no: 2 specifically binds.
Biogen Idec Ma Inc.


Lrp-8 binding proteins


The disclosure provides binding proteins that specifically bind to lrp-8 and optionally cross the blood brain barrier (bbb), localize to the brain and/or localize to the spinal cord.. .
Abbvie Inc.


Dual variable region antibody-like binding proteins having cross-over binding region orientation


The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins..
Sanofi


Polypeptide targeting to mitochondria


Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a dna-binding polypeptide, fused to a mitochondrial targeting sequence (mts) and a nuclear export signal (nes), and the encoded proteins.
Medical Research Council


Method for recovering proteins from waste water discharged during process of producing fish meat processed product


According to the present invention, a method for recovering useful fish meat proteins from waste water generated during fish paste or fishmeal production is provided. The provided is a method for recovering water-soluble proteins from fish paste leaching waste water or stick water, comprising: adjusting the ph of fish paste leaching waste water or stick water to 4.5-5.5 to insolubilize water-soluble proteins; heating the insolubilized proteins to 30° c.
Maruha Nichiro Corporation


Diagnosis and treatment of mycobacteria infections


The invention provides isolated, purified, recombinant receptor binding proteins gp-6, gp-10 and gp-31 from mycobacterium phage l5, and methods for producing these recombinant receptor binding proteins. The invention also provides the use of recombinant receptor binding proteins, including gp-6, gp-10 and gp-31, as probes for the identification and diagnosis of mycobacterium infections and conditions caused by mycobacterium.
The Governors Of The University Of Alberta


Methods for inducing the differentiation of blood monocytes into functional dendritic cells


Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood and produce a leukocyte concentrate comprising monocytes and plasma containing proteins.
Yale University


Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


Antigen binding proteins


The present invention concerns antigen binding proteins and fragments thereof which specifically bind b cell maturation antigen (bcma), particularly human bcma (hbcma) and which inhibit the binding of baff and april to the bcma receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods..
Glaxo Group Limited


Reducing or non-reducing polynucleotide polymer for drug delivery and preparing same


The present invention relates to a reducing or non-reducing polynucleotide polymer for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer. The present invention relates to a drug delivery carrier for delivering proteins or peptides to a targeted area through electrostatic attraction, by obtaining a negatively (−) charged polymer by using nucleotides to synthesize the reducing or non-reducing polymer, which is easily breakable due to disulfide bonds, and then bonding the negatively (−) charged polymer with a positively (+) charged protein or peptide, wherein a polymer derived from a non-viral drug delivery carrier containing the novel reducing or non-reducing polymer is capable of effectively enabling escape of a drug, delivered by means of proton buffering activity, from an endosome to other organelles in a cell..
Utah-inha Dds & Advanced Therapeutics Research Center


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Protein-enriched tobacco-derived composition


The present disclosure describes methods of obtaining and/or deriving proteins from plants of the nicotiana species and methods for incorporation of such proteins into various products. For example, a method for obtaining a protein-enriched material from a plant of the nicotiana species or portion thereof is provided, comprising: extracting one or more proteins from the plant material into a solvent to form a liquid protein-containing extract; separating a solid extracted plant material from the liquid protein-containing extract; clarifying the liquid protein-containing extract to form a clarified protein-containing extract and a solids fraction; and treating the clarified protein-containing extract so as to provide a protein-enriched material comprising at least about 60% protein by weight..
R.j. Reynolds Tobacco Company


Compositions and methods for increasing bone mineralization


A novel class or family of tgf-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules..

Intein-modified enzymes, their production and industrial application


A method of predicting an intein insertion site in a protein that will lead to a switching phenotype is provided. The method includes identifying a plurality of c/t/s sites within the protein; selecting from the plurality of c/t/s/sites those that are ranked 0.75 or higher by a support vector machine, within ten angstroms of the active site of the protein, and at or near a loop-β-sheet junction or a loop-α-helix junction.

Formulation for stabilizing proteins, which is free of mammalian excipient


The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, wherein the formulation is free of stabilising proteins.. .

Means and methods for the generation of mammalian producer cells for the production of recombinant proteins


The present invention relates to the generation of mammalian cells capable of producing proteins at an industrial scale and means and methods to obtain and use said cells, in particular for protein production.. .

Methods and compositions relating to anti-il-21 receptor antibodies


The present invention provides compositions and methods relating to antigen binding proteins against il-21 receptor.. .

Tnf-alpha binding proteins


Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (tnf-α), e.g., human tnf-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies..

Methods and compositions for enhancing targeted transgene integration


Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of r loop formation or inhibitors of r-loop repair and/or one or more up-regulators of the tc-ner pathway to the target cell.. .
Sangamo Biosciences, Inc.


Biocatalytical composition


The present invention relates to means and methods for protecting proteins and protein-type compounds in industrial and other applications. In particular, the invention provides a composition comprising at least one protein or protein-type compound immobilized at the surface of a solid carrier embedded in a protective material.
Inofea Gmbh


Antibodies directed to her-3 and uses thereof


The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Amgen, Inc.


Methods and compositions for labeling polypeptides


Synthesis of many proteins is tightly controlled at the level of translation and plays an essential role in fundamental processes such as cell growth and proliferation, signaling, differentiation or death. Methods that allow imaging and identification of nascent proteins allow for dissecting regulation of translation, both spatially and temporally, including in whole organisms.
President And Fellows Of Harvard College


Chromatography matrices including novel staphylococcus aureus protein a based ligands


The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation


Inhibitors of transcription factors and uses thereof


The present invention provides novel compounds of any one of formulae (i) to (iv), and pharmaceutically compositions thereof. Compounds of any one of formulae (i) to (iv) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (bets)).
University Of Massachusetts


Vaccine formulations that induce a th2 immune response


The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.


Amdinocillin for rapid determination of susceptibility to beta-lactam antibiotics


Described are methods for detecting susceptibility of a specimen to antibiotics, and particularly for enhancing such susceptibility testing for beta lactam antibiotics and antibiotics that bind to penicillin-binding proteins. The method comprises contacting the specimen with an oligonucleotide probe that specifically hybridizes with a target nucleic acid sequence region of ribosomal rna.
United States Government Represented By The Department Of Veterans Affairs


Polymers and plastics derived from animal proteins


The invention is directed to a method for preparing a polymer derived from an animal protein, such as in a feedstock derived from animal by-products. The method involves hydrolyzing proteins present in a feedstock to obtain hydrolyzed proteins, wherein hydrolysis is conducted under conditions sufficient to digest the proteins and destroy pathogens; extracting a protein fraction from the hydrolyzed proteins; and treating the protein fraction with a crosslinking reagent to form the polymer.
The Governors Of The University Of Alberta


Antibodies to matrix metalloproteinase 9


The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof


Non-naturally occurring factor h binding proteins derived from variant 3 fhbp that can elicit antibodies that are bactericidal for at least one strain of n. Meningitidis, and methods of use of such proteins, are provided.
Children's Hospital & Research Center Oakland


Affinity tags and processes for purifying and immobilizing proteins using same


The present disclosure provides affinity tags, fusion proteins comprising one or more affinity tags, compositions comprising a fusion protein, methods of purifying a protein using an affinity tag, and devices for purifying a protein using an affinity tag.. .
University Of Washington Through Its Center For Commercialization


Instant view of protein bands


Apparatus, reagents, pre-treated proteins and methods for dying proteins in electrophoresis run gels, and for instantly viewing such dyed protein samples in an electrophoresis gel. A protein mixing solution containing a fluorescence dye is mixed with a protein sample so that fluorescence dyes within the protein mixing solution conjugate to proteins within the protein sample.

System and retrieval treatment of proteins in formalin-fixed paraffin-embedded tissue section


A protein retrieval treatment system used for activating proteins contained in a deparaffinized tissue section obtained by removing paraffin from a formalin-fixed paraffinembedded tissue section. The protein retrieval treatment system includes: a dispensing unit for dispensing a retrieval treatment solution over a dispensing area including a measurement area on the deparaffinized tissue section; and a moist-heat treatment unit for heating, in a saturated water vapor, the deparaffinized tissue section with the dispensing area covered with the retrieval treatment solution..
Shizuoka Prefecture


Antibody binding sites specific for egfrviii


This application describes binding proteins that specifically bind to egfrviii and multispecific binding proteins that specifically bind to egfrviii and cd3. Further described is a multispecific tandem diabody that binds to egfrviii and cd3.
Affimed Gmbh


Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide


Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv (scfv) fragments, as well as chimeric antigen receptors.
Memorial Sloan-kettering Cancer Center


Antigen binding proteins capable of binding thymic stromal lymphopoietin


The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (tslp), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-tslp antibodies and derivatives of such antibodies.
Amgen Inc.


Rational solubilising proteins


A method and data processing system for identifying mutations or insertions that alter a property such as the solubility or aggregation propensity of an input polypeptide chain. The method comprises inputting a sequence of amino acids and a structure for said sequence for said target polypeptide chain; calculating a structurally corrected solubility or aggregation propensity profile for said target polypeptide chain; selecting, using said calculated profile, regions within said target polypeptide chain; identifying at least one position within each selected region suitable for mutations or insertions; generating a plurality of mutated sequences by mutations or insertions at least one identified position; and predicting a value of the solubility or aggregation propensity for each of the plurality of mutated sequences whereby any alteration to the solubility or aggregation propensity of the input polypeptide chain is identified.
Cambridge Enterprise Limited


Chemistry, systems and methods of translocation of a polymer through a nanopore


Embodiments disclosed herein are directed to recognition tunneling systems, methods and devices, and more particularly, to chemical reactions for selectively labeling proteins and peptides and placing protein and/or peptides into, or onto a nanopore formed in a solid support and threading such in and/or through the nanopore, with such nanopores, in some embodiments, including a molecular motor to pull or otherwise force the protein/peptide through the nanopore.. .
Arizona Board Of Regents Acting For And On Behalf Of Arizona State University


Genetically encoded sensors for imaging proteins and their complexes


Isolated truncated and mutated sensor proteins derived from flavoproteins that are 12-20 kda or less, genetically encoded for detection and imaging of protein complexes having long fluorescent lifetimes that can be 4.0 ns or greater.. .
President And Board Of Trustees Of Santa Clara College


Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof


The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Amgen Inc.


Cb-1 receptor antigen-binding proteins and uses thereof


This disclosure relates to cb1 receptor antigen-binding proteins, e.g. Antibodies and methods of using the cb1 receptor antibodies.
Amgen Inc.


Il-21 binding proteins and uses thereof


The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (il-21) and uses thereof, e.g., in therapy.. .
Monash University


Human antibodies binding to rsv g proteins


The disclosure provides isolated antibodies and antigen-binding fragments that bind to the g protein of rsv and which are capable of neutralizing rsv.. .
Crucell Holland B. V.


Novel genes involved in biosynthesis


The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited


Oncostatin m receptor antigen binding proteins


The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Biogen Ma Inc.


Il-1 family variants


The present invention provides compositions and methods relating to il-1rrp2 requiring proteins.. .
Amgen Inc.


Method for producing autologous proteins


A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
Arthrogen Gmbh


Computer-implemented methods of determining protein viscosity


The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag


Thermophilic and thermoacidophilic glycosylation genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods


Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for glycosylating and/or post-translationally modifying proteins using isolated and/or purified polypeptides and nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc.


Antibodies to human signal peptide-containing proteins


The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


Cmv neutralizing antigen binding proteins


The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (cmv). Also encompassed by the invention are antigen binding proteins that have been humanized.
Board Of Regents Of The University Of Texas System




G Proteins topics:
  • G Proteins
  • Antibodies
  • Immunoglobulin
  • Metalloprotein
  • Chemotherapeutic Agent
  • Kinase Inhibitor
  • Tetrapeptide
  • Apoptosis Protein
  • Topoisomerase
  • Peptidomimetic
  • Fractionation
  • Medical Treatment
  • Chromatograph
  • Encapsulation
  • Electrospraying


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.4199

    4863

    1 - 1 - 105